Compare · RMD vs RMED
RMD vs RMED
Side-by-side comparison of ResMed Inc. (RMD) and Ra Medical Systems Inc. (RMED): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and RMED operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 5061.2x RMED ($6.7M).
- RMD has hit the wire 9 times in the past 4 weeks while RMED has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 1 for RMED).
- Company
- ResMed Inc.
- Ra Medical Systems Inc.
- Price
- -
- -
- Market cap
- $34.07B
- $6.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 1
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Ra Medical Systems Inc.
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light and is used as a tool in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target
Latest RMED
- SEC Form SC 13G filed by Ra Medical Systems Inc.
- Ra Medical Systems Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Jenkins David A bought $9,786 worth of shares (19,056 units at $0.51), increasing direct ownership by 6% to 329,856 units (SEC Form 4)
- Jenkins David A bought $7,086 worth of shares (16,940 units at $0.42), increasing direct ownership by 6% to 310,800 units (SEC Form 4)
- Jenkins David A bought $6,323 worth of shares (16,263 units at $0.39), increasing direct ownership by 6% to 293,860 units (SEC Form 4)
- SEC Form SC 13D/A filed by Ra Medical Systems Inc. (Amendment)
- Ra Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 4 filed by Thomassen Margrit
- SEC Form 4 filed by Francis, John P.
- New insider Francis, John P. claimed ownership of 2,611 shares (SEC Form 3)